Table 4.
CSF ELISA testing of patients (DCM) > < 6 month.
| CSF ELISA testing | DCM > 6 month | DCM < 6 month | P* | ηp2 |
|---|---|---|---|---|
| M [SD] | M [SD] | |||
| Angiogenic mediators | N = 13 | N = 9 | ||
| Angiopoietin 2 (pg/ml) | 250.0 [85.3] | 275.8 [76.3] | .52 | .02 |
| VEGF C (pg/ml) | 162.0 [103.6] | 149.2 [97.8] | .69 | .01 |
| VEGF A (pg/ml) | 15.6 [9.8] | 14.4 [7.5] | .73 | .01 |
| Inflammatory mediators | N = 11 | N = 8 | ||
| IL1 beta (pg/ml) | .8 [.4] | 3.2 [7.6] | .35 | .06 |
| IL 8 (pg/ml) | 72.3 [95.8] | 69.3 [50.5] | .90 | .00 |
| Rantes (pg/ml) | 5.3 [13.7] | 0.8 [.6] | .33 | .06 |
CSF cerebrospinal fluid, DCM degenerative cervical myelopathy, pg/ml picogram per milliliter, M mean, SD standard deviation, TAAA thoracic-abdominal aortic aneurysm.
*p values reflect the univariate post-hoc between group tests revealed by the MANOVAs; ηp2 = partial eta squared effect size.
Italic values indicate significance level of p < .05.